Second Warning Letter Directed At Boston Scientific’s Chemotherapy Ports
This article was originally published in The Gray Sheet
Executive Summary
FDA cites Boston Scientific for quality system regulation violations related to the firm's valved Vaxcel chest ports and catheters in an Aug. 1 1warning letter
You may also be interested in...
Boston Scientific Shipped Defective Taxus Stents, FDA Warning Letter Says
Boston Scientific's third warning letter since May faults the firm for shipping defective Taxus drug-eluting stents and not adequately addressing the quality system problem once it was discovered
Boston Scientific Shipped Defective Taxus Stents, FDA Warning Letter Says
Boston Scientific's third warning letter since May faults the firm for shipping defective Taxus drug-eluting stents and not adequately addressing the quality system problem once it was discovered
FDA Cites Boston Scientific For GMP Violations In Warning Letter
Boston Scientific plans to meet with FDA the week of June 6 to discuss corrective measures to fix "serious regulatory problems" with the firm's Vaxcel low profile infusion ports